Optimizing early-phase immunotherapy trials: the role of biomarker enrichment strategies
Immune checkpoint inhibitors have revolutionized the treatment of solid tumors; however, their clinical efficacy remains limited to a subset of patients. Novel immunotherapy agents are being investigated in phase I clinical trials, with an increasing f…